NCT04919551已完成1 期
A Clinical Trial to Evaluate the Effect of Food on PK and PD of Vicagrel Capsules in Healthy Adult Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- AUC
研究概览
简要总结
This clinical study will adopt a randomized, open-label, single-dose, 3-cycle, 3-way crossover design to explore the PK and PD profiles of a single oral dose of vicagrel capsules under fasted and fed conditions in health subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Voluntary signing of informed consent before the trial, and full understanding of the experimental content, process and possible ARs;
- •Able to complete the study according to the protocol;
- •Subjects (and their partners) are willing to take effective contraceptive measures from screening to 6 month after the last dose of the IMPs. See Appendix 5 for specific contraceptive measures;
- •Male and female subjects aged 18 to 45 years (inclusive);
- •Male weight ≥50 kg, female weight ≥ 45 kg. Body mass index (BMI) = body weight (kg) / height2 (m2). BMI ranging from 18 to 28 kg/m2 (including critical values);
- •Physical examination and vital signs are normal or abnormal without clinical significance.
排除标准
- •More than 5 cigarettes per day on average 3 months before the trial;
- •Allergic constitution (allergic to multiple drugs and foods), or known to be possibly allergic to drugs of the same class of the IMP or highly sensitive to clopidogrel;
- •History of alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine); history of drug abuse or use of hard drug within the past five years;
- •Blood donation or massive blood loss (>450 mL) within 3 months before screening;
- •Presence of dysphagia or history of any gastrointestinal and hepatic, renal disease (whether cured or not) or history of surgery that affects absorption or excretion of the IMP within 6 months prior to screening;
- •With any disease that increases the risk of bleeding, such as acute gastritis, stomach and duodenal ulcers, or history of abnormal bleeding (e.g. bleeding time prolonged after tooth extraction);
- •The subject or his or her immediate family member has a family history of coagulation or haemorrhagic disorders (such as haemophilia)/symptoms (such as hematemesis, melena, severe or recurrent epistaxis, coughing blood (hemoptysis), obvious hematuria or intracranial hemorrhage), or suspected vascular malformation, such as aneurysm or early-onset stroke;
- •Took potent inhibitors and/or inducers of CYP enzymes (CYP1A2, 2A6, 2C8, 2C19, 3A4 and 3A5) within 28 days prior to the first dose. Potent inhibitors of CYP enzymes include ciprofloxacin, clopidogrel, itraconazole, ketoconazole, ritonavir, troleandomycin, etc.. Potent inducers of CYP enzymes include rifampicin, carbamazepine, phenytoin sodium, St. John's wort, etc.. See Appendix 6 for details;
- •Took any prescription, non-prescription, any vitamin or herbal drugs within 14 days before the first dose;
- •Had foods that affect CYP3A4 metabolism within 2 weeks prior to the first dose, such as grapefruit or grapefruit-containing beverages, or had intense physical exercise (e.g. strength training, aerobic training, and playing football) within 7 days prior to the first dose, or other factors affecting drug absorption, distribution, metabolism, excretion, etc.;
- •Recently there have been major changes in diet or exercise habits;
- •Participated in a another clinical study within 3 months prior to screening (a subject may be enrolled if he/she withdraws from the study prior to treatment, i.e., the subject is not randomized or doesn't receive treatment);
- •Failure to tolerate high-fat meals (two boiled eggs, one slice of toast with butter and bacon, a box of French fries, a glass of whole milk);
- •12-lead ECG abnormalities have clinical significance;
- •Female subjects who are in lactation or positive for serum pregnancy test in the screening period or during the trial;
- •Clinical laboratory abnormalities have clinical significance or other clinically significant diseases before screening (including but not limited to gastrointestinal, kidney, liver, nerve, blood, endocrine, tumor, and lung, immune, mental or cardiovascular and cerebrovascular diseases);
- •Positive for viral hepatitis (including hepatitis B and C), HIV antibody and treponema pallidum antibody during screening;
- •Any acute diseases or concomitant medicines from screening period to before taking the IMPs;
- •Took chocolate, any food or drink with caffeine or xanthine within 24 hours before the first dose;
- •Took any alcoholic product or alcohol breath test is positive within 24 hours before the first dose;
- •Urine drug screening positive;
- •The investigator believes that there are other factors that are not suitable for participating in the trial.
研究组 & 干预措施
KGD
Experimental
Oral administration after fasting/high-fat meal/low-fat meal
干预措施: vicagrel (Drug)
GDK
Experimental
Oral administration after high-fat meal/low-fat meal/fasting
干预措施: vicagrel (Drug)
DKG
Experimental
Oral administration after low-fat meal/fasting/high-fat meal
干预措施: vicagrel (Drug)
结局指标
主要结局
AUC
时间窗: 48 hours
Area Under the Curve From Time Zero to Last Quantifiable Concentration
Cmax
时间窗: 48 hours
Peak concentration
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Food Effect on Pharmacokinetic Profiles of VV116 Administered Orally to Chinese Healthy VolunteersHealthy SubjectsNCT05221138Vigonvita Life Sciences12
已完成
1 期
A Study to Investigate the Effect of Food on the Pharmacokinetics of HSG4112ObesityNCT04733001Glaceum12
已完成
1 期
A Study of RO5045337 in Patients With Solid TumorsNeoplasmsNCT01164033Hoffmann-La Roche76
已完成
1 期
A Randomized, Open-label, Single-dose, Crossover Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of Dilatrend SR 64mg Capsule After Oral Administration in Healthy Male VolunteersChronic Stable AnginaNCT01340248Chong Kun Dang Pharmaceutical24
已完成
1 期
Clinical Study to Evaluate the Food Effect of CKD-383 0.5/25/1000mg in Healthy VolunteersType 2 Diabetes Mellitus (T2DM)NCT06695598Chong Kun Dang Pharmaceutical30